Marcello Bigarella
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Graduate Student Researcher
Research Areas
Biography and Research Information
OverviewAI-generated summary
Marcello Bigarella's research focuses on the application of advanced imaging techniques in clinical settings. His recent work includes a phase II diagnostic trial investigating the addition of 18F-DCFPyL PSMA PET to MRI to potentially avoid unnecessary biopsies in men undergoing active surveillance for prostate cancer. This trial, known as PROMPT, aims to improve diagnostic accuracy and patient management.
Another area of his investigation involves analyzing pathologic findings and clinical outcomes in patients with renal cell carcinoma who have undergone immune checkpoint blockade followed by deferred consolidative nephrectomy. Bigarella collaborates with researchers at the University of Arkansas for Medical Sciences, including Neriman Gökden, with whom he has co-authored one publication. His research is characterized by a strong emphasis on evaluating and improving diagnostic and therapeutic strategies for various medical conditions.
Metrics
- Publications: 1
Selected Publications
-
Addition of 18F-DCFPyL PSMA PET to MRI to avoid unnecessary biopsy in men on active surveillance: Final results from a phase II diagnostic trial (PROMPT). (2026)
-
Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy. (2026)
Collaboration Network
Top Collaborators
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
- Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
Similar Researchers
Based on overlapping research topics